We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Insulin, Neurogenetics and Memory in Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00018382
Recruitment Status : Completed
First Posted : July 5, 2001
Last Update Posted : January 21, 2009
Sponsor:
Information provided by:

Study Description
Brief Summary:
This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: rosiglitazone Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Masking: Double
Primary Purpose: Treatment
Official Title: Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic Approach
Study Start Date : October 1999
Estimated Study Completion Date : March 2003


Arms and Interventions


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Men and women with mild Alzheimer's Disease without serious medical or psychiatric comorbid conditions.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00018382


Locations
United States, Washington
VA Puget Sound Health Care System
Seattle, Washington, United States, 98108
Sponsors and Collaborators
VA Office of Research and Development
Investigators
OverallOfficial: Steven Kahn, M.D.
OverallOfficial: Sanjay Asthana, M.D.
OverallOfficial: Alfred Fujimoto, M.D.
More Information

ClinicalTrials.gov Identifier: NCT00018382     History of Changes
Other Study ID Numbers: AGCG-012-98S
First Posted: July 5, 2001    Key Record Dates
Last Update Posted: January 21, 2009
Last Verified: December 2004

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Rosiglitazone
Hypoglycemic Agents
Physiological Effects of Drugs